Quarterly report [Sections 13 or 15(d)]

EMPLOYEE STOCK PLANS

v3.25.4
EMPLOYEE STOCK PLANS
3 Months Ended
Nov. 30, 2025
EMPLOYEE STOCK PLANS  
EMPLOYEE STOCK PLANS

NOTE 7 – EMPLOYEE STOCK PLANS

The Company reserved 2.0 million shares of common stock for issuance to employees and directors pursuant to the Company’s 2024 Equity Incentive Plan (the “2024 Equity Plan”). As of November 30, 2025, there were 1,929,996 shares available for grant under the 2024 Equity Plan. Prior to the effective date of the 2024 Equity Plan, the Company granted options and stock awards to eligible participants under its 2014 Equity Plan (the “2014 Equity Plan”), which expired on April 12, 2024.

The following table summarizes the combined stock option activity for the 2014 Equity Plan and 2024 Equity Plan for the periods noted:

  ​ ​ ​

Number of Options

  ​ ​ ​

Weighted Average Exercise Price

  ​ ​ ​

Weighted Average Remaining Contractual Term

  ​ ​ ​

Approximate Aggregate Intrinsic Value
(in thousands)

Outstanding at August 31, 2025

489,500

$

9.54

3.7

$

598

Granted

 

30,000

10.75

Exercised

 

(10,000)

4.05

Forfeited / Expired

Outstanding at November 30, 2025

 

509,500

9.70

4.0

1,003

Options exercisable at November 30, 2025

 

479,500

$

9.64

3.6

$

984

Outstanding at August 31, 2024

 

524,500

$

9.42

4.7

$

877

Granted

 

Net settlement exercised

 

(35,000)

7.89

Forfeited / Expired

Outstanding at November 30, 2024

 

489,500

$

9.52

3.4

$

2,455

During the three months ended November 30, 2025, the Company issued 10,000 shares pursuant to the exercise of stock options for cash. During the three months ended November 30, 2024, the Company issued 13,815 shares pursuant to the net settlement of stock options, whereby the optionee did not pay cash for the options exercised but instead received the number of shares equal to the difference between the exercise price and the market price on the date of exercise, with 21,185 options being cancelled as a result of those net  in settlements.

The following table summarizes the activity and value of non-vested options under the 2014 Equity Plan and 2024 Equity Plan for the periods presented:

  ​ ​ ​

Number of Options

  ​ ​ ​

Weighted Average Grant Date Fair Value

Non-vested options outstanding at August 31, 2025

17,000

$

3.93

Granted

 

30,000

4.12

Vested

 

(17,000)

3.93

Forfeited / Expired

 

Non-vested options outstanding at November 30, 2025

 

30,000

$

4.12

Non-vested options outstanding at August 31, 2024

 

59,000

$

4.45

Granted

 

Vested

 

(42,000)

4.66

Forfeited

Non-vested options outstanding at November 30, 2024

 

17,000

$

3.93

All non-vested options are expected to vest.

On September 17, 2025, the Company issued certain employees 5,000 shares of restricted stock. These shares vested 20% at the September 17, 2025 grant date, and 20% will vest on each anniversary of the grant date for four years subject to continued employment. On September 17, 2025, the Company also issued an employee 10,000 unrestricted shares of common stock. The shares are eligible to vote and participate in any dividend or stock splits approved by the Company.  On November 20, 2025, the Company issued an employee

a stock options to purchase 30,000 shares of common stock with a grant-date fair value of $4.12 per share and a three-year vesting term which expires ten years from the grant date.

On September 18, 2024, the Company issued certain employees 8,000 shares of restricted stock. These shares vested 20% at the September 18, 2024 grant date, and 20% will vest on each anniversary of the grant date for four years subject to continued employment. On September 18, 2024, the Company also issued an employee 1,200 shares of restricted stock.  One third of these shares vested at the September 18, 2024 grant date, and the remaining shares will vest in one-third increments on each anniversary of the grant date for two years subject to continued employment. The shares are eligible to vote and participate in any dividend or stock splits approved by the Company.

For the three months ended November 30, 2025, the Company recognized $0.1 million of stock-based compensation expense. For the three months ended November 30, 2024, the Company recognized less than $0.1 million of stock-based compensation expense.

At November 30, 2025, the Company had unrecognized compensation expenses totaling $0.2 million relating to non-vested options and restricted stock that are expected to vest. The weighted-average period over which these options and shares of restricted stock are expected to vest is approximately two years.